Immunomodulation and immunopharmacology in heart failure

Markousis-Mavrogenis, George; Baumhove, Lukas; Al-Mubarak, Ali A.; Aboumsallem, Joseph Pierre; Bomer, Nils; Voors, Adriaan A.; van der Meer, Peter

doi:10.1038/s41569-023-00919-6

Cited by 10 publications

(6 citation statements)

References 382 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low lymphocyte counts are associated with a high risk of mortality in patients with heart failure 9 . In patients with heart failure, lymphopenia may be associated with inflammation, malnutrition, peripheral congestion, and beta‐adrenergic activation 10–15 . Mechanisms of peripheral congestion may lead to lymphocyte loss and endotoxin transfer, and endotoxin may induce apoptosis of specific subtypes of lymphocytes, resulting in lymphocytopenia 10–12 .…”

Section: Introductionmentioning

confidence: 99%

“…Mechanisms of peripheral congestion may lead to lymphocyte loss and endotoxin transfer, and endotoxin may induce apoptosis of specific subtypes of lymphocytes, resulting in lymphocytopenia 10–12 . Sustained sympathetic‐adrenergic activation may result in a decrease in circulating lymphocytes 14,15 . The prevalence of malnutrition in heart failure patients is estimated to be between 15% and 90%, and nutritional status has become an important indicator for assessing prognosis 16 .…”

Section: Introductionmentioning

confidence: 99%

“… 9 In patients with heart failure, lymphopenia may be associated with inflammation, malnutrition, peripheral congestion, and beta‐adrenergic activation. 10 , 11 , 12 , 13 , 14 , 15 Mechanisms of peripheral congestion may lead to lymphocyte loss and endotoxin transfer, and endotoxin may induce apoptosis of specific subtypes of lymphocytes, resulting in lymphocytopenia. 10 , 11 , 12 Sustained sympathetic‐adrenergic activation may result in a decrease in circulating lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

“… 10 , 11 , 12 Sustained sympathetic‐adrenergic activation may result in a decrease in circulating lymphocytes. 14 , 15 The prevalence of malnutrition in heart failure patients is estimated to be between 15% and 90%, and nutritional status has become an important indicator for assessing prognosis. 16 Cheng et al demonstrated that a high prognostic nutritional index (PNI, calculated by albumin level and lymphocyte count) was independently associated with a lower risk of mortality in patients with heart failure.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure

Liu,

Gong,

Wang

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsThe combination of haemoglobin, albumin, lymphocytes, and platelets (HALP) is a new metric used to assess patient prognosis in many diseases. This study aimed to assess the relationship between HALP and short‐ and long‐term mortality in patients with heart failure.Methods and resultsThis retrospective cohort study included adult patients with heart failure who were hospitalized between 2019 and 2021. The primary outcomes were 1‐month mortality and 1‐year mortality. The multivariable logistic regression analysis was used to evaluate the association between HALP and the risk of mortality. Stratified analyses were conducted based on New York Heart Association functional classification (NYHA) stage (II/III, IV) and left ventricular ejection fraction (LVEF, <50%, ≥50%). The area under the receiver operating characteristic curve (AUC) was used to evaluate the ability of HALP, prognostic nutritional index (PNI), C‐reactive protein (CRP), and the Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC‐HF) risk score in predicting mortality in patients with heart failure. A total of 730 patients with heart failure were included, of whom 61 (8.36%) died within 1 month and 77 (10.55%) died within 1 year. High HALP scores were associated with a reduced risk of 1‐month mortality (odds ratio (OR) = 0.978, 95% confidence interval (CI): 0.963–0.992, P = 0.003) and 1‐year mortality (OR = 0.987, 95% CI: 0.977–0.997, P = 0.009) in patients with heart failure. In patients with different NYHA stages or LVEF levels, high HALP scores were correlated with a reduced risk of 1‐year mortality in patients with NYHA stage II/III (OR = 0.978, 95% CI: 0.957–1.000, P = 0.045) or LVEF ≥50% (OR = 0.970, 95% CI: 0.945–0.996, P = 0.024). The AUC for HALP, PNI, CRP, and MAGGIC‐HF to predict 1‐year mortality in patients with heart failure were 0.677 (95% CI: 0.619–0.735), 0.666 (95% CI: 0.608–0.723), 0.638 (95% CI: 0.572–0.704), and 0.654 (95% CI: 0.591–0.717), respectively.ConclusionsHALP may be a potential marker for predicting mortality in patients with heart failure. Further exploration based on HALP may yield better clinical predictors of prognosis in patients with heart failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure

Liu,

Gong,

Wang

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

show abstract

“…A number of non-genetic factors have been proposed as contributors to the pathogenesis of NDs, including (but not limited to): (1) the abundance and composition of the gut microbiome 16 , 17 , (2) a history of infection with viral or bacterial pathogens 18 , (3) the existence of subjacent or overt cardiovascular and metabolic disorders 19 , as well as (4) dysfunctions of the innate or adaptive immune system 20 , 21 (Box 1 ). Recent data from other biomedical disciplines point indeed to an underappreciated contribution of dysregulated immunity to the pathogenesis of disorders that have classically been attributed to cell-intrinsic mechanisms, including various cardiovascular conditions 22 , 23 and cancer 24 . Moreover, microglial cells, which play a major role in the development of multiple NDs (see below), are brain-resident cells of hematopoietic origin with macrophage-like functions, which render them preferential interactors of other potentially pathogenic immune cells 25 .…”

Section: Introductionmentioning

confidence: 99%

Immunological aspects of central neurodegeneration

Niso-Santano,

Fuentes,

Galluzzi

2024

Cell Discov

View full text Add to dashboard Cite

The etiology of various neurodegenerative disorders that mainly affect the central nervous system including (but not limited to) Alzheimer’s disease, Parkinson’s disease and Huntington’s disease has classically been attributed to neuronal defects that culminate with the loss of specific neuronal populations. However, accumulating evidence suggests that numerous immune effector cells and the products thereof (including cytokines and other soluble mediators) have a major impact on the pathogenesis and/or severity of these and other neurodegenerative syndromes. These observations not only add to our understanding of neurodegenerative conditions but also imply that (at least in some cases) therapeutic strategies targeting immune cells or their products may mediate clinically relevant neuroprotective effects. Here, we critically discuss immunological mechanisms of central neurodegeneration and propose potential strategies to correct neurodegeneration-associated immunological dysfunction with therapeutic purposes.

show abstract